Transapical transcatheter mitral valve replacement with apical tethering system. Single-center mid-term results

Clicks: 11
ID: 327204
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #109 of 147 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: In high-risk patients, transcatheter mitral valve replacement (TMVR) is an alternative to surgery and transcatheter edge-to-edge repair (TEER). This study aims to evaluate the mid-term results of TMVR with the Tendyne System in a real-world population at a single center. METHODS: Between November 2018 and December 2023, all consecutive patients undergoing TMVR with the Tendyne System were included. The primary outcomes were overall and cardiovascular death. Secondary outcomes included the absence of mitral regurgitation (MR) >mild, improved functional status and device success, as defined by the Mitral Valve Academic Research Consortium criteria. RESULTS: Thirty patients were included. Mean age was 74.6±7.1 years, with a mean EuroScore 2 of 7.7±3.8%. MR was severe in 90% of cases and moderate with concomitant stenosis in 10%; 57% of patients were in NYHA class III-IV, and left ventricular ejection fraction was 42±13%. Technical success was 100%; 30-day mortality was 3.3%; there was no MR > mild; 4 (13%) patients had mild MR; and the mean transvalvular gradient was 3.7±1.1 mmHg. At a median follow-up of 2.8 (IQR 2) years, overall mortality was 50% and cardiovascular mortality was 27%, and we had no device-related complications, apart from one case of bacterial endocarditis that was medically treated. None of the patients presented MR >mild; the mean transvalvular gradient was 2.9±1.7 mmHg. At the latest follow-up, the device success rate was 100%, and NYHA class II was observed in 94% of patients, compared with 43% at baseline (p < 0.001); however, 30% have had a rehospitalization for acute heart failure during FU. CONCLUSIONS: In high-risk patients, TMVR with the Tendyne device is associated with acceptable procedure-related morbidity and mortality and leads to mid-term improvement in functional class; however, mid-term survival remains poor.
Reference Key
openalex_W7204851752 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Laura Besola, Cristina Di Franco, Federico Giorgi, Danilo Ruggiero, Giosuè Falcetta, Michele Celiento, G Ravenni, Cristina Giannini, Andrea Colli
Are you one of these authors? Claim your profile
Journal Interdisciplinary CardioVascular and Thoracic Surgery
Year 2026
DOI
10.1093/icvts/ivag194
URL
https://academic.oup.com/icvts/advance-article-pdf/doi/10.1093/icvts/ivag194/70883191/ivag194.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.